Advertisement
INCY vs REGN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Buy and REGN is a Buy.
INCY in upward trend: price rose above 50-day moving average on November 06, 2026
INCY moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Oscillator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INCY as a result. In 61 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for INCY just turned positive on October 20, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in 23 of 35 cases over the following month. The odds of a continued upward trend are 66%.
Following a +3.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 205 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 61 cases where INCY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
INCY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INCY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.823) is normal, around the industry mean (3.498). P/E Ratio (14.717) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (440.869).
REGN in upward trend: 10-day moving average crossed above 50-day moving average on October 26, 2026
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 62 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 203 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 186 of 264 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The 10-day RSI Indicator for REGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 21 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 48%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 64 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.498). P/E Ratio (21.599) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (440.869).
INCY | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 44 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 25 | 64 | |
SMR RATING 1..100 | 33 | 59 | |
PRICE GROWTH RATING 1..100 | 43 | 7 | |
P/E GROWTH RATING 1..100 | 70 | 13 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (88) in the Biotechnology industry is in the same range as INCY (92). This means that REGN’s stock grew similarly to INCY’s over the last 12 months.
INCY's Profit vs Risk Rating (25) in the Biotechnology industry is somewhat better than the same rating for REGN (64). This means that INCY’s stock grew somewhat faster than REGN’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is in the same range as REGN (59). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.
REGN's Price Growth Rating (7) in the Biotechnology industry is somewhat better than the same rating for INCY (43). This means that REGN’s stock grew somewhat faster than INCY’s over the last 12 months.
REGN's P/E Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for INCY (70). This means that REGN’s stock grew somewhat faster than INCY’s over the last 12 months.
| INCY | REGN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 63% | 1 day ago 48% |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 68% |
| MACD ODDS (%) | 1 day ago 66% | 1 day ago 66% |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 65% |
| Advances ODDS (%) | 1 day ago 63% | 1 day ago 64% |
| Declines ODDS (%) | 7 days ago 56% | 5 days ago 57% |
| BollingerBands ODDS (%) | 1 day ago 57% | 1 day ago 53% |
| Aroon ODDS (%) | 1 day ago 52% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 2 FA rating(s) are green while REGN’s FA Score has 2 green FA rating(s).
- INCY’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 6 bullish TA indicator(s).
- INCY’s TA Score: 5 bullish, 4 bearish.
- REGN’s TA Score: 6 bullish, 4 bearish.
Price Growth
INCY (@Biotechnology) experienced а +1.54% price change this week, while REGN (@Biotechnology) price change was -4.30% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was -8.97%, and the average quarterly price growth was +85.13%.
Reported Earning Dates
INCY is expected to report earnings on Feb 09, 2027.
REGN is expected to report earnings on Jan 29, 2027.
Industries' Descriptions
@Biotechnology (+2.23% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | +1.73% | ||
| VRTX - REGN | 42% Loosely correlated | +0.69% | ||
| EXEL - REGN | 41% Loosely correlated | +3.12% | ||
| RPRX - REGN | 41% Loosely correlated | +2.18% | ||
| INCY - REGN | 39% Loosely correlated | +1.87% | ||
| BMRN - REGN | 35% Loosely correlated | +2.05% | ||
More | ||||